Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema

Jianmin Wang; Mohamed Ibrahim; Peykan Turkcuoglu; Elham Hatef; Afsheen Khwaja; Roomasa Channa; Diana V. Do; Quan Dong Nguyen

doi:10.3109/09273948.2010.483317

Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema

Jianmin Wang, Mohamed Ibrahim, Peykan Turkcuoglu, Elham Hatef, Afsheen Khwaja, Roomasa Channa, Diana V. Do, Quan Dong Nguyen

School of Medicine

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Purpose: To describe the bioactivity of an intercellular adhesion molecule inhibitor (efalizumab) in a patient with refractory uveitic macular edema. Methods: A 55-year-old man presented with idiopathic autoimmune uveitis and associated macular edema, which could not be controlled by regional and systemic corticosteroid and selected immunomodulatory therapy. Efalizumab was administered as subcutaneous injections. Results: After 37 weekly injections of efalizumab, the uveitic macular edema was successfully eliminated. Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation. Conclusion: Further investigation of the role of intercellular adhesion molecule inhibitors in the management of uveitic macular edema is indicated.

Original language	English (US)
Pages (from-to)	395-398
Number of pages	4
Journal	Ocular Immunology and Inflammation
Volume	18
Issue number	5
DOIs	https://doi.org/10.3109/09273948.2010.483317
State	Published - Oct 2010

Keywords

ICAM inhibitor
Macular edema
Uveitis

ASJC Scopus subject areas

Immunology and Allergy
Ophthalmology

Access to Document

10.3109/09273948.2010.483317

Cite this

@article{7213280895e44b58b5c5a7fe384e1726,

title = "Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema",

abstract = "Purpose: To describe the bioactivity of an intercellular adhesion molecule inhibitor (efalizumab) in a patient with refractory uveitic macular edema. Methods: A 55-year-old man presented with idiopathic autoimmune uveitis and associated macular edema, which could not be controlled by regional and systemic corticosteroid and selected immunomodulatory therapy. Efalizumab was administered as subcutaneous injections. Results: After 37 weekly injections of efalizumab, the uveitic macular edema was successfully eliminated. Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation. Conclusion: Further investigation of the role of intercellular adhesion molecule inhibitors in the management of uveitic macular edema is indicated.",

keywords = "ICAM inhibitor, Macular edema, Uveitis",

author = "Jianmin Wang and Mohamed Ibrahim and Peykan Turkcuoglu and Elham Hatef and Afsheen Khwaja and Roomasa Channa and Do, {Diana V.} and Nguyen, {Quan Dong}",

note = "Funding Information: Dr. Wang is a recipient of the Kangzhe Advanced Study Abroad Scholarship from the Chinese Ophthalmological Society. Dr. Nguyen is a recipient of a Physician Scientist Award from the Research to Prevent Blindness Foundation. Correspondence: Quan Dong Nguyen, MD, MSc, Johns Hopkins Hospital, 600 North Wolfe Street, Maumenee 745, Baltimore, MD 21287, USA. E-mail: qnguyen4@jhmi.edu Funding Information: Funding: Dr. Wang is a recipient of the Kangzhe Advanced Study Abroad Scholarship from the Chinese Ophthalmological Society. Dr. Nguyen is a recipient of a Physician Scientist Award from the Research to Prevent Blindness Foundation.",

year = "2010",

month = oct,

doi = "10.3109/09273948.2010.483317",

language = "English (US)",

volume = "18",

pages = "395--398",

journal = "Ocular Immunology and Inflammation",

issn = "0927-3948",

publisher = "Informa Healthcare",

number = "5",

}

TY - JOUR

T1 - Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema

AU - Wang, Jianmin

AU - Ibrahim, Mohamed

AU - Turkcuoglu, Peykan

AU - Hatef, Elham

AU - Khwaja, Afsheen

AU - Channa, Roomasa

AU - Do, Diana V.

AU - Nguyen, Quan Dong

N1 - Funding Information: Dr. Wang is a recipient of the Kangzhe Advanced Study Abroad Scholarship from the Chinese Ophthalmological Society. Dr. Nguyen is a recipient of a Physician Scientist Award from the Research to Prevent Blindness Foundation. Correspondence: Quan Dong Nguyen, MD, MSc, Johns Hopkins Hospital, 600 North Wolfe Street, Maumenee 745, Baltimore, MD 21287, USA. E-mail: qnguyen4@jhmi.edu Funding Information: Funding: Dr. Wang is a recipient of the Kangzhe Advanced Study Abroad Scholarship from the Chinese Ophthalmological Society. Dr. Nguyen is a recipient of a Physician Scientist Award from the Research to Prevent Blindness Foundation.

PY - 2010/10

Y1 - 2010/10

N2 - Purpose: To describe the bioactivity of an intercellular adhesion molecule inhibitor (efalizumab) in a patient with refractory uveitic macular edema. Methods: A 55-year-old man presented with idiopathic autoimmune uveitis and associated macular edema, which could not be controlled by regional and systemic corticosteroid and selected immunomodulatory therapy. Efalizumab was administered as subcutaneous injections. Results: After 37 weekly injections of efalizumab, the uveitic macular edema was successfully eliminated. Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation. Conclusion: Further investigation of the role of intercellular adhesion molecule inhibitors in the management of uveitic macular edema is indicated.

AB - Purpose: To describe the bioactivity of an intercellular adhesion molecule inhibitor (efalizumab) in a patient with refractory uveitic macular edema. Methods: A 55-year-old man presented with idiopathic autoimmune uveitis and associated macular edema, which could not be controlled by regional and systemic corticosteroid and selected immunomodulatory therapy. Efalizumab was administered as subcutaneous injections. Results: After 37 weekly injections of efalizumab, the uveitic macular edema was successfully eliminated. Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation. Conclusion: Further investigation of the role of intercellular adhesion molecule inhibitors in the management of uveitic macular edema is indicated.

KW - ICAM inhibitor

KW - Macular edema

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=77956828128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956828128&partnerID=8YFLogxK

U2 - 10.3109/09273948.2010.483317

DO - 10.3109/09273948.2010.483317

M3 - Article

C2 - 20666682

AN - SCOPUS:77956828128

SN - 0927-3948

VL - 18

SP - 395

EP - 398

JO - Ocular Immunology and Inflammation

JF - Ocular Immunology and Inflammation

IS - 5

ER -

Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this